<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR25">
 <label>25.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Parker</surname>
    <given-names>CC</given-names>
   </name>
   <name>
    <surname>James</surname>
    <given-names>ND</given-names>
   </name>
   <name>
    <surname>Brawley</surname>
    <given-names>CD</given-names>
   </name>
   <name>
    <surname>Clarke</surname>
    <given-names>NW</given-names>
   </name>
   <name>
    <surname>Hoyle</surname>
    <given-names>AP</given-names>
   </name>
   <name>
    <surname>Ali</surname>
    <given-names>A</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial</article-title>
  <source>Lancet (London, England)</source>
  <year>2018</year>
  <volume>392</volume>
  <fpage>2353</fpage>
  <lpage>2366</lpage>
  <pub-id pub-id-type="doi">10.1016/S0140-6736(18)32486-3</pub-id>
 </element-citation>
</ref>
